Assessing Transporter-Mediated DDIs

How technology can help you draw conclusions on DDI risk and clinical significance for your target patient population

Evaluating drug-drug interactions (DDIs) early in development allows you to assess potential concomitant medication risk for your target patient population and determine whether a dedicated DDI clinical study is necessary. A thorough DDI analysis helps you move forward with confidence and ensure that patients can safely take new medications with their existing treatments.

This comprehensive white paper discusses the complexities of transporter-mediated DDIs and explores how Certara’s Drug Interaction Database or DIDB can help streamline the evaluation process using scientist-curated in vitro and clinical datasets.

Submit the form to download your free copy of the transporter-mediated DDI white paper today

Learn more about the complexities of transporter-based DDIs compared to CYP-mediated interactions and the valuable insights into transporter-based drug interactions available through the DIDB platform.

The white paper outlines practical strategies for leveraging DIDB to:

Evaluate a new molecular entity or NME’s inhibitory potential on transporters

Identify relevant transporter substrates administered in your target patient population

Assess drug interaction clinical significance of these co-medications

Determine whether a dedicated clinical DDI study is necessary

Download the white paper

Simply fill out the form and download the expert-led white paper for free!

About the authors

Isabelle Ragueneau-Majlessi, MD, MS

Senior Director

Dr. Ragueneau is a Clinical Professor Emeritus from the University of Washington where she co-founded the Drug Interaction Database or DIDB over 25 years ago. At Certara, she is the head of the Drug Interaction Solutions program and leads the Center of Excellence in Drug Interaction Science. She is a clinical pharmacologist by training, with a deep expertise in the evaluation of drug-drug interactions mechanisms and clinical significance. In 2022, she received the Gary Neil prize for innovation in drug development from the ASCPT in recognition of her extensive work with the DIDB and the impact of the tool on drug interaction research.

Jingjing Yu, MD, PhD

Director

Dr. Yu joined Certara in 2023 following the acquisition of the University of Washington Drug Interaction Solutions program. With over 15 years of experience in drug metabolism and clinical pharmacology, she brings a unique expertise in the field of drug interactions, gained through her work in both academia and industry. At Certara, Dr. Yu is Director at the Drug Interaction Solutions and a core member of Center of Excellence in Drug Interaction Science. She is also an Affiliate Associate Professor of the Department of Pharmaceutics at the University of Washington in Seattle, WA.

About Certara

Certara is dedicated to transforming drug discovery and development for good. We harness the power of biosimulation, advanced analytics, and regulatory expertise to create a future where treatments reach patients faster and more efficiently.

From discovery to market access and commercial, we tailor solutions to meet our clients’ most pressing challenges. Through strategic leadership and advanced predictive technologies, Certara provides comprehensive solutions to optimize drug development processes, reduce risks, and improve outcomes. Our clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.